Reviewed by Michael Gill, B. Sc.

What Are Veltassa Clinical Trials?

Veltassa is the brand name for the medication known as Patiromer, a medication used to lower potassium in the blood. When there is too much potassium in the blood, a blood condition known as hyperkalemia occurs, and it could be fatal.

Veltassa clinical trials are conducted to determine its safety and efficacy as a treatment for high potassium levels. High potassium levels often signal serious underlying health conditions, and as such, Veltassa clinical trials are conducted to determine if it is a wise medication to use with specific conditions.

Why Is Veltassa Being Studied In Clinical Trials?

The medication known as Veltassa has not been used for very long, as it was only 2015 when Veltassa was approved by the Federal Drug Administration (FDA). Unfortunately, it can sometimes be difficult for doctors to determine when is the best time to use Veltassa to treat high potassium. That is because high potassium levels can be life threatening, and the human body does not respond quickly enough to Veltassa to overcome high potassium levels in a life threatening situation.

As such, continued Veltassa clinical trials are always recommended in order to determine what medication combinations work best for patients with high potassium.

How Does Veltassa Treatment Work?

In a normal human system, potassium is typically taken in by the diet and excreted by the kidneys. In a body with high potassium levels, the potassium is not being excreted properly, and this is a sign that other key functions in the body may not be working well. When that happens, medical intervention is required in order to bring the body back to its original homeostasis with potassium levels.

Veltassa works to bring the human body back to its normal homeostasis on patients where potassium levels are not dangerously high. It is a slow acting medication that balances potassium levels without compromising organ systems in the process.

What Are Some of the Breakthrough Clinical Trials Involving Veltassa?

2011: In this double-blind and placebo- controlled study that was run prior to the FDA approval of Veltassa, Veltassa was used, along with a placebo, to determine its effectiveness in lowering hyperkalaemia rates. A total of 105 patients were used, all with a history of hyperkalaemia, and were given either the medication or the placebo for a total of four weeks. Results indicated a positive result with lower incidence of hyperkalaemia reported in the medical control group.

Who Are The Key Opinion Leaders On Veltassa Clinical Trial Research?

Bertram Pitt, M.D.

Dr. Bertram Pitt is a Professor of Internal Medicine at the University of Michigan School of Medicine, and is a lead researcher in the field of internal medicine. His career has been spent publishing more than 500 articles on the topic of cardiovascular disease and its underlying dysfunction. He has performed numerous clinical trials on the efficacy of Veltassa, long before its FDA approval, and recommends it as an effective treatment of hyperkalaemia, acknowledging that it could be an indicator of a potential underlying heart problem.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 16th, 2021

Last Reviewed: November 23rd, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.